KH
Kevin Hammon
Vice President at EQT Life Sciences
Amsterdam, North Holland
Overview
Kevin Hammon is currently serving as the Vice President at EQT Life Sciences in Amsterdam, North Holland, specializing in venture capital investments in pharmaceuticals, digital health, and biotech sectors. With a background in pharmacology and extensive experience in clinical research, Kevin has successfully navigated roles at BioMarin Pharmaceutical Inc., Amgen, and Baxter International Inc., showcasing expertise in pharmacokinetics, immunocytochemistry, and biopharmaceuticals.
Work Experience
Vice President
2024 - Current
EQT Life Sciences, formerly LSP, is one of Europe’s largest and most experienced healthcare investors, targeting innovative life sciences and health care companies. With a track record going back 30 years, EQT Life Sciences has raised more than €3 billion, and invested in over 150 private companies.
Investment Associate
2022 - 2024
Life Sciences Securities Research
2022 - 2022
Sr Research Associate, Clinical Pharmacology (DMPK, PKPD, Pharmacometrics)
2020 - 2020
Research Associate II, Clinical Pharmacology (DMPK, PKPD, Pharmacometrics)
2018 - 2020
Research Associate I, Clinical Pharmacology (DMPK, PKPD, Pharmacometrics)
2016 - 2018
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
Raised $585,800,000.00.
Associate, Clinical Pharmacology Modeling and Simulation
2015 - 2016
Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases.
Raised $28,500,000,000.00 from Citibank and Bank of America.
Quality Analyst I
2014 - 2015
Education
Master of Business Administration - MBA
2021 - 2021
Graduate Certificate
2017 - 2018
Bachelor's Degree
2012 - 2014